Peter Richardson

USPTO Granted Patents = 13 (Patent Applications = 14)

CIPO Patents = 4

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 4.5

ph-index = 7

Forward Citations = 287(Granted Patents)

Location History:

Shoreline, WA (US) (2013)
Ringoes, NJ (US) (2012 - 2024)

Company Filing History:

Seattle Children's Hospital

patents

Years Active: 2012-2024

Loading Chart...

13 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11998591 - Method of treating diabetes type 2 by administering ultrarapid acting insulin (2024-06-04),

2. 11304992 - Inhalable dry powder pharmaceutical composition (2022-04-19),

3. 10857207 - Method of treating diabetes type 2 by administering ultrarapid acting insulin (2020-12-08),

4. 9943571 - Use of ultrarapid acting insulin (2018-04-17),

5. 9078866 - Method for treating hyperglycemia with GLP-1 (2015-07-14),

6. 8921311 - Method for treating hyperglycemia (2014-12-30),

7. 8642548 - Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome (2014-02-04),

8. 8623817 - Method of treating diabetes type 2 by administering ultrarapid acting insulin (2014-01-07),

9. 8499759 - Broad-band, low frequency, high-amplitude, long time duration, oscillating airway pressure breathing apparatus and method utilizing bubbles (2013-08-06),

10. 8381723 - Broad-band, low frequency, high-amplitude, long time duration, oscillating airway pressure breathing apparatus and method utilizing bubbles (2013-02-26),

11. 8377869 - Method of preventing adverse effects by GLP-1 (2013-02-19),

12. 8372804 - Delivery of active agents (2013-02-12),

13. 8119593 - Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin (2012-02-21),

Title: The Innovative Contributions of Peter Richardson

Introduction

Peter Richardson is a notable inventor based in Ringoes, NJ, who has made significant contributions to the field of diabetes treatment. With a total of 11 patents to his name, Richardson's work focuses on improving the management of hyperglycemia and diabetes, particularly type 2 diabetes.

Latest Patents

Among his latest patents is a method of treating type 2 diabetes by administering ultrarapid acting insulin. This innovative approach involves a combination of ultrarapid acting insulin and insulin glargine, which is administered in a specific manner to optimize treatment outcomes. Another significant patent is for an inhalable dry powder pharmaceutical composition aimed at treating hyperglycemia and diabetes. This method is particularly beneficial for patients with type 2 diabetes mellitus who have elevated fasting blood glucose levels, utilizing a formulation that includes a GLP-1 molecule and diketopiperazine delivered via pulmonary inhalation.

Career Highlights

Throughout his career, Peter Richardson has worked with prominent companies in the pharmaceutical industry, including Mannkind Corporation and Smith & Nephew Pte. Limited. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in diabetes care.

Collaborations

Richardson has collaborated with several professionals in his field, including Robert A Baughman and Elizabeth Potocka. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his inventions.

Conclusion

Peter Richardson's work exemplifies the spirit of innovation in the medical field, particularly in diabetes treatment. His patents reflect a commitment to improving patient outcomes and advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.